GLTO

Insider Trades

Name	Value	Action	Price	Current Price
Firmani LoriChief Financial Officer $2.9k135 shares SellJan 2, 2026 $21.41 --
Schambye Hans T.Director, Officer: Chief Executive Officer $15k700 shares SellJan 2, 2026 $21.38 --
Winslow GarrettGeneral Counsel $5.5k255 shares SellJan 2, 2026 $21.38 --
Firmani LoriInterim CFO $498147 shares SellJul 3, 2025 $3.39 --
Schambye Hans T.Director, Officer: Chief Executive Officer $2.5k735 shares SellJul 3, 2025 $3.38 --
Winslow GarrettGeneral Counsel $881260 shares SellJul 3, 2025 $3.39 --

News

zacks.comWhat Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?zacks.comApr 20

Trade GLTO

About Galecto, Inc.

Galecto, Inc. is a clinical-stage biotechnology company focused on creating new therapeutic agents for a range of illnesses, including fibrotic conditions, cancer, and inflammation. Its most advanced investigational drug, GB2064, is currently undergoing Phase IIa clinical studies to treat myelofibrosis. The company is also developing GB0139, an inhalable compound that targets galectin-3, which is in Phase IIb trials for severe fibrotic lung disorders, such as idiopathic pulmonary fibrosis (IPF)—a serious and progressively worsening lung disease. Additionally, Galecto is advancing GB1211, a selective oral galectin-3 inhibitor, with ongoing Phase IIa trials for cancer and Phase Ib/IIa trials for fibrosis. Founded in 2011, Galecto, Inc. is headquartered in Boston, Massachusetts.

CEO: Lori C. Firmani
IPO Date: Oct 29, 2020

Market Data

Open: $22.26
High: $23.54
Low: $21.58
Volume: 609
Avg Volume: 224.7K
52W High: $38.33
52W Low: $2.01

Valuation

Market Cap: $34M
Enterprise Value: $775M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-6.7M
Revenue: $0
Net Income: $-210M
Cash: $258M
Debt: $68k

Events

EarningsAug 5

EPS est. -0.447